Anthim market seen reaching $6.13 million by 2030

The Business Research Company says the global Anthim market is expanding on biodefense demand, rising infection concerns and higher healthcare spending. The market is projected to grow from $4.3 million in 2025 to $6.13 million by 2030, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Anthim is a niche biodefense treatment market, so growth signals continued spending on anthrax preparedness, emergency stockpiles and targeted antibody therapies. - The forecast points to more demand for countermeasures as governments and health systems prioritize biosecurity and rapid-response treatment capabilities.

What happened: - The Business Research Company released a global Anthim market report projecting the market will rise from $4.3 million in 2025 to $4.63 million in 2026. - The report puts the market at $6.13 million by 2030, implying a 7.3% CAGR from 2026 to 2030. - The report says North America held the largest share of the market in 2025. - The report says Asia-Pacific is expected to post the fastest growth over the forecast period. - The company also published a free sample report and full market report online: Download the free sample and View the full report.

The details: - Anthim is a monoclonal antibody therapy designed to treat inhalational anthrax caused by Bacillus anthracis. - The therapy works by binding to anthrax toxin and blocking it from entering human cells. - The report ties 2025-2026 growth to bioterrorism preparedness, government funding for biodefense, proven monoclonal antibody effectiveness, strategic national stockpile programs and emergency-use regulatory approvals. - The report says future growth will be supported by biodefense investment, pandemic-readiness efforts, biosecurity priorities, emergency response upgrades, antibody manufacturing improvements and long-term government procurement contracts. - Key trends listed in the report include larger stockpiles of anthrax countermeasures, broader government preparedness programs, wider monoclonal antibody adoption in biodefense, stronger emergency response protocols and faster therapy deployment. - The report says rising bacterial infection rates are a growth driver, citing WHO data that suspected anthrax cases in Zambia rose from 42 between September 2022 and January 2023 to 684 by Nov. 20, 2023, with four deaths. - The report says chronic disease prevalence is also supporting demand, citing IHME data that more than half a billion people were living with diabetes in June 2023 and that figure is expected to reach 1.3 billion by 2050. - The report says higher healthcare spending is another tailwind, citing UK Office for National Statistics data showing total healthcare expenditure rose 5.6% nominally from 2022 to 2023. - The report says its 2026 editions include market-attractiveness scoring, total addressable market analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables.

Between the lines: - The report mixes direct biodefense demand with broader healthcare trends, suggesting the market is being shaped by both public-sector preparedness and wider spending on advanced therapies. - The regional split points to an established U.S.-led market with faster future growth likely coming from countries expanding healthcare and biodefense investment.

What's next: - The market will likely depend on continued government procurement, emergency stockpile policy and investment in antibody manufacturing capacity. - The report flags pandemic readiness and biosecurity as longer-term demand drivers, suggesting further growth if those priorities stay elevated. - The Business Research Company lists contact details for sales and media inquiries, including Saumya Sahay at marketing@tbrc.info.

The bottom line: - Anthim remains a small market, but the report expects steady expansion through 2030 as biodefense and emergency-response spending stay in focus.